Pfizer-BioNTech is seeking to expand the availability of its COVID-19 vaccine by requesting authorization from the Food and Drug Administration for children ages five and under. Data from a phase 2/3 trial of the vaccine included 1,678 children who had received a third dose during the period when the Omicron coronavirus variant dominated. Results of the trial […]